tumor-targeted split IL-12 therapy (Alkermes)

N/A

Report date: 2025/03/20 10:04:10

Base Information

Drug Nametumor-targeted split IL-12 therapy (Alkermes)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-12 receptor stimulants
TargetsInterleukin-12 receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAlkermes Plc
China Registration ClassN/A

Develop Information

Active CompaniesMural Oncology Inc
Inactive CompaniesAlkermes Plc
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A